

polypeptide of any one of claims 1 to 6 or conducting *in vitro* or *in vivo* cellular-based tests employing the hybrid polypeptide of any one of claims 1 to 6.

REMARKS

Claims 1-7, 9, 13-15 and 20-25 are pending in the current application. Claims 1-7, 9 and 13-15 have been amended to conform to domestic practice. Claims 8, 10-12 and 16-19 have been canceled. Claims 20-25 have been added to conform canceled claims 8, 10-12 and 16-19 to domestic practice. Support for the amendments to claims 1-7, 9 and 13-15 and for new claims 20-25 is found in, *inter alia*, original claims 1-19. This amendment is believed to introduce no new matter, and thus, its entry is respectfully requested.

Applicants believe that the present application is in condition for examination. If for any reason, the Examiner believes that personal communication will expedite prosecution of this application, then the Examiner is invited to contact the undersigned at the phone number provided.

Respectfully submitted,

SHANKS & HERBERT

By: Toni Junell Herbert
Toni-Junell Herbert
Reg. No. 34,348

Date: 12/27/01

TransPotomac Plaza
1033 N. Fairfax Street
Suite 306
Alexandria, VA 22314
(703) 683-3600